Document Detail


Sparstolonin B Attenuates Hypoxia-Induced Apoptosis, Necrosis and Inflammation in Cultured Rat Left Ventricular Tissue Slices.
MedLine Citation:
PMID:  25117676     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
PURPOSE: Ischemia/reperfusion results in tissue damage, a rapid increase in cytokines and chemokines and inflammatory cell infiltration. Herein we investigated the ability of a selective TLR2/4 antagonist, Sparstolonin B (SsnB), to protect rat cultured left ventricular tissue (LV) slices from hypoxic injury by inhibiting the myocardial inflammatory response independent of inflammatory cell infiltration.
METHODS AND RESULTS: Media Lactate dehydrogenase (LDH) levels were measured to reflect hypoxia-induced cytotoxicity and cell injury with and without SsnB. Incubation with SsnB (15 and 30 μM) significantly reduced by 20 and 40 %, respectively, the amount of LDH released from the hypoxic LV slices. TUNEL staining showed that SsnB significantly attenuated the levels of hypoxia-induced apoptotic cells from 61.5 ± 4.0 to 27.0 ± 2.1 (15 μM SsnB) and 23.5 ± 2.2 (30 μM SsnB) cells/unit area. Similarly, the Periodic Acid-Schiff (PAS) staining of ischemic areas in untreated hypoxic LV slices was increased 17 fold from 0.26 ± 0.09 to 4.41 ± 0.43 %, while in hypoxic slices incubated with 15 and 30 μM of SsnB, the PAS positive ischemic areas were increased by only 6.4 fold to 1.66 ± 0.39 % and 3.8 fold to 1.00 ± 0.22 %, respectively. Rt-PCR confirmed that MCP1 and IL-6 expression during hypoxia was elevated by 2 and 4 fold, respectively, while their up-regulation was significantly inhibited (i.e., <0.7 fold increase) by SsnB.
CONCLUSION: The selective TLR2/4 antagonist, Sparstolonin B, can substantially protect LV myocardium via its ability to inhibit injury resulting from hypoxic myocardial-generated inflammation. Accordingly SsnB has potential as a therapeutic agent for the attenuation of myocardial ischemia-reperfusion injury.
Authors:
Qing Liu; Jianping Li; Shaiban Jubair; Dawei Wang; Yi Luo; Daping Fan; Joseph S Janicki
Related Documents :
1929826 - Limb salvage vs amputation for critical ischemia. the role of vascular surgery.
9847986 - Feasibility and safety of percutaneous laser revascularization using the biosense syste...
1384836 - Coronary vascularization in patient maintained on chronic hemodialysis.
23057006 - Protective role of fibrates in cardiac ischemia/reperfusion.
519666 - Regional 99m technetium diphosphonate uptake in experimental dog heart infarct: relatio...
22595816 - Management of non-st-segment elevation acute coronary syndrome: comparison of the updat...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-8-13
Journal Detail:
Title:  Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy     Volume:  -     ISSN:  1573-7241     ISO Abbreviation:  Cardiovasc Drugs Ther     Publication Date:  2014 Aug 
Date Detail:
Created Date:  2014-8-13     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8712220     Medline TA:  Cardiovasc Drugs Ther     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Silencing of microRNA-122 is an early event during hepatocarcinogenesis from nonalcoholic steatohepa...
Next Document:  Paternal factor V Leiden and recurrent pregnancy loss: a new concept behind fetal genetics?: reply.